On November 12, 2019, the Board of Directors of Cardiovascular Systems, Inc. elected Stephen Stenbeck as a Class III director. The Board of Directors also appointed Mr. Stenbeck as the Chair of the Audit, Risk Management and Finance Committee (the Audit Committee), effective immediately upon the expiration of Brent Blackey’s term as a Class II director of the Company, which expires at the Annual Meeting of Stockholders to be held on November 13, 2019. As previously disclosed, Mr. Blackey will no longer serve as a director following the expiration of his term at the Annual Meeting. As Chair of the Audit Committee, Mr. Stenbeck will also be the Company’s audit committee financial expert. Stenbeck is a retired partner of Ernst & Young LLP.